1202 related articles for article (PubMed ID: 25475955)
21. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
[TBL] [Abstract][Full Text] [Related]
22. Vaccination against canine leishmaniosis increases the phagocytic activity, nitric oxide production and expression of cell activation/migration molecules in neutrophils and monocytes.
Moreira ML; Costa-Pereira C; Alves ML; Marteleto BH; Ribeiro VM; Peruhype-Magalhães V; Giunchetti RC; Martins-Filho OA; Araújo MS
Vet Parasitol; 2016 Apr; 220():33-45. PubMed ID: 26995719
[TBL] [Abstract][Full Text] [Related]
23. LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4⁺ and CD8⁺) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis.
Aguiar-Soares RD; Roatt BM; Ker HG; Moreira Nd; Mathias FA; Cardoso JM; Gontijo NF; Bruna-Romero O; Teixeira-Carvalho A; Martins-Filho OA; Corrêa-Oliveira R; Giunchetti RC; Reis AB
Parasit Vectors; 2014 Feb; 7():61. PubMed ID: 24507702
[TBL] [Abstract][Full Text] [Related]
24. Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis.
Anand S; Madhubala R
Sci Rep; 2015 Jun; 5():10706. PubMed ID: 26035062
[TBL] [Abstract][Full Text] [Related]
25. miR-21 Expression Determines the Early Vaccine Immunity Induced by
Gannavaram S; Bhattacharya P; Siddiqui A; Ismail N; Madhavan S; Nakhasi HL
Front Immunol; 2019; 10():2273. PubMed ID: 31608064
[TBL] [Abstract][Full Text] [Related]
26. Live attenuated Leishmania infantum centrin deleted mutant (LiCen
Zarei Z; Mohebali M; Dehghani H; Khamesipour A; Tavakkol-Afshari J; Akhoundi B; Abbaszadeh-Afshar MJ; Alizadeh Z; Eskandari SE; Asl AD; Razmi GR
Comp Immunol Microbiol Infect Dis; 2023 Jun; 97():101984. PubMed ID: 37119594
[TBL] [Abstract][Full Text] [Related]
27. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
[TBL] [Abstract][Full Text] [Related]
28. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A
J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.
Saldarriaga OA; Travi BL; Park W; Perez LE; Melby PC
Vaccine; 2006 Mar; 24(11):1928-40. PubMed ID: 16310897
[TBL] [Abstract][Full Text] [Related]
30. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
[TBL] [Abstract][Full Text] [Related]
31. Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis.
Fernandes CB; Junior JT; de Jesus C; Souza BM; Larangeira DF; Fraga DB; Tavares Veras PS; Barrouin-Melo SM
Vaccine; 2014 Mar; 32(11):1287-95. PubMed ID: 24406392
[TBL] [Abstract][Full Text] [Related]
32. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
Nogueira FS; Moreira MA; Borja-Cabrera GP; Santos FN; Menz I; Parra LE; Xu Z; Chu HJ; Palatnik-de-Sousa CB; Luvizotto MC
Vaccine; 2005 Sep; 23(40):4805-10. PubMed ID: 16011864
[TBL] [Abstract][Full Text] [Related]
33. Vaccination with a CD4
Dias DS; Ribeiro PAF; Martins VT; Lage DP; Costa LE; Chávez-Fumagalli MA; Ramos FF; Santos TTO; Ludolf F; Oliveira JS; Mendes TAO; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
Transl Res; 2018 Oct; 200():18-34. PubMed ID: 29908151
[TBL] [Abstract][Full Text] [Related]
34. A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum.
Pirdel L; Farajnia S
Scand J Immunol; 2017 Jul; 86(1):15-22. PubMed ID: 28426153
[TBL] [Abstract][Full Text] [Related]
35. Gentamicin-attenuated Leishmania infantum vaccine: protection of dogs against canine visceral leishmaniosis in endemic area of southeast of Iran.
Daneshvar H; Namazi MJ; Kamiabi H; Burchmore R; Cleaveland S; Phillips S
PLoS Negl Trop Dis; 2014 Apr; 8(4):e2757. PubMed ID: 24743691
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil.
Borja-Cabrera GP; Santos FN; Bauer FS; Parra LE; Menz I; Morgado AA; Soares IS; Batista LM; Palatnik-de-Sousa CB
Vaccine; 2008 Sep; 26(39):4991-7. PubMed ID: 18675868
[TBL] [Abstract][Full Text] [Related]
37. Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation.
Roatt BM; Aguiar-Soares RD; Vitoriano-Souza J; Coura-Vital W; Braga SL; Corrêa-Oliveira R; Martins-Filho OA; Teixeira-Carvalho A; de Lana M; Figueiredo Gontijo N; Marques MJ; Giunchetti RC; Reis AB
PLoS One; 2012; 7(11):e49780. PubMed ID: 23189161
[TBL] [Abstract][Full Text] [Related]
38. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.
Dey R; Dagur PK; Selvapandiyan A; McCoy JP; Salotra P; Duncan R; Nakhasi HL
J Immunol; 2013 Mar; 190(5):2138-49. PubMed ID: 23338240
[TBL] [Abstract][Full Text] [Related]
39. Characterization of cross-protection by genetically modified live-attenuated Leishmania donovani parasites against Leishmania mexicana.
Dey R; Natarajan G; Bhattacharya P; Cummings H; Dagur PK; Terrazas C; Selvapandiyan A; McCoy JP; Duncan R; Satoskar AR; Nakhasi HL
J Immunol; 2014 Oct; 193(7):3513-27. PubMed ID: 25156362
[TBL] [Abstract][Full Text] [Related]
40. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas.
Palatnik-de-Sousa CB; Silva-Antunes I; Morgado Ade A; Menz I; Palatnik M; Lavor C
Vaccine; 2009 Jun; 27(27):3505-12. PubMed ID: 19464528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
